STAb Therapeutics

We are a biotech spin-off developing an innovative cell therapeutic platform to create next generation cell therapies in oncology. Our products - STAb Therapeutics - have been developed based on solid discoveries from our team of scientific founders at the Hospital 12 de Octubre in Madrid. We are harnessing cell engineering techniques to develop a new wave of cell therapies capable of efficiently redirecting the immune system with our STAb Therapeutics. Our technological approach involves a T cell redirecting strategy that combines principles of adoptive cell therapy and bispecific antibodies. This approach is based on the in vivo production of T cell-engagers (TCE) by engineered cells, which results in effective serum concentrations of TCE, expansion and persistence of adoptively transferred STAb – T cells, and polyclonal recruitment of both modified and unmodified bystander T cells present at the tumor microenvironment. We have validated the therapeutic potential of STAb -T cells in B-cell and T cell hematological malignancies, and we aim to develop this platform to provide new therapeutic solutions to both hematological and solid tumors.